Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Hydroxyurea tolerated well in sickle cell patients

Dauvergne B et al. FSCDR 2018 (annual meeting of the Foundation for Sickle Cell Disease Research), presentation JSCDH-D-18-00052.

Key clinical point: Hydroxyurea has been well tolerated by children and adults with sickle cell disease.

Major finding: Of adult participants, 16.9% have experienced hydroxyurea-related adverse events.

Study details: Observational 10-year study of 2,000 adults and children with SCD who were taking hydroxyurea.

Disclosures: The study was sponsored by Addmedica, which markets hydroxyurea as Siklos. Dr. Dauvergne is employed by Addmedica.

Source: Dauvergne B et al. FSCDR 2018 (annual meeting of the Foundation for Sickle Cell Disease Research), presentation JSCDH-D-18-00052.

Read the article.

Citation:

Dauvergne B et al. FSCDR 2018 (annual meeting of the Foundation for Sickle Cell Disease Research), presentation JSCDH-D-18-00052.

This Week's Must Reads

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018

Must Reads in Anemia

Systematic review examines sickle cell trait complications, Naik RP et al. Ann Intern Med. 2018 Oct 30. doi:10.7326/M18-1161

Post hoc analysis of SUSTAIN shows efficacy of crizanlizumab, Kutlar A et al. Am J Hematol. 2018 Oct 8. doi: 10.1002/ajh.25308

Integrated programs ease sickle cell pain, hospitalizations, Annual meeting of the Foundation for Sickle Cell Disease Research

Fewer sickle cell crises with L-glutamine use, Niihara Y et al. N Engl J Med. 2018 Jul 19;379(3):226-35.

Observational study shows hydroxyurea well tolerated in sickle cell disease, Dauvergne B et al. FSCDR 2018, presentation JSCDH-D-18-00052